Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Aug

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

An Egyptian Surgical Oncologist Urges Global Cooperation to Achieve Equitable Cancer Care

Using ctDNA to Measure Molecular Residual Disease in Patients With Colorectal Cancer

Mechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients With Cancer

Study Finds Cytarabine Prodrug Active and Safe in Older Compromised Patients With AML

Use of Statins and Survival Outcomes Among Patients With Triple-Negative Breast Cancer